Asthma stepwise management acc to GINA guidelines
Reading File
Finding Sources
Finding Sources
Searching the Web
GINA 2024 2025 asthma stepwise management guidelines steps
Finding Sources
Reading Web Page
https://ginasthma.org/wp-content/uploads/2025/11/GINA-Summar…
Searching PubMed
"asthma" AND "GINA" AND "stepwise management"
Finding Sources
Searching Images
GINA asthma stepwise management treatment steps diagram
Loading Image
Reading Web Page
https://www.pulmonologyadvisor.com/features/gina-2025-asthma…
Here is a comprehensive overview of GINA 2025 Asthma Stepwise Management — the most current update as of May 2025.
GINA 2025: Asthma Stepwise Management
Core Framework: Personalised Asthma Management
GINA uses an Assess → Adjust → Review cycle tailored to individual patient needs. The guiding principle is that no patient should be on SABA alone — all patients need an ICS-containing reliever or controller.
Adults & Adolescents (≥12 years) — 5-Step Approach
GINA 2025 retains the two-track system introduced in 2020–21:
| Track 1 (PREFERRED) | Track 2 (Alternative) | |
|---|---|---|
| Reliever | Low-dose ICS-formoterol (as-needed) | SABA (but check adherence first) |
| Advantage | Single inhaler across Steps 1–4; ↓65% emergency visits vs SABA alone | Accessible in low/middle-income settings |
| Note | Reduces severe exacerbations significantly | Medium-to-high dose ICS-LABA changed to medium-dose at Step 4 in 2025 update |
Track 1 Steps (Preferred)
| Step | Controller | Reliever | Notes |
|---|---|---|---|
| Step 1 | None | Low-dose ICS-formoterol as-needed | For infrequent symptoms; no daily controller needed |
| Step 2 | None | Low-dose ICS-formoterol as-needed | For mild persistent symptoms; still as-needed only |
| Step 3 | Low-dose ICS-formoterol (daily maintenance) | Low-dose ICS-formoterol as-needed | MART begins (Maintenance And Reliever Therapy) |
| Step 4 | Medium-dose ICS-formoterol (daily maintenance) | Low-dose ICS-formoterol as-needed | MART continues; e.g., Symbicort 200/6 |
| Step 5 | Medium-dose ICS-formoterol + add-ons | Low-dose ICS-formoterol as-needed | Add LAMA (tiotropium); refer for phenotype/biologic assessment |
MART uses ICS-formoterol as both controller and reliever. This works because formoterol is a fast-onset LABA. ICS-LABA inhalers without formoterol cannot be used as MART.
Track 2 Steps (Alternative)
| Step | Controller | Reliever |
|---|---|---|
| Step 1 | None (but take low-dose ICS with each SABA dose) | SABA |
| Step 2 | Low-dose ICS daily | SABA |
| Step 3 | Low-dose ICS-LABA (e.g., Seretide 50 Evohaler) | SABA |
| Step 4 | Medium-dose ICS-LABA (changed in 2025 from medium-to-high) | SABA |
| Step 5 | As per Step 5 above; add-on LAMA, biologics | SABA |
Step 5 — Severe Asthma Management
If uncontrolled despite Step 4, refer to specialist. Investigations include:
- Blood eosinophil count (BEC) and FeNO — T2 biomarkers (measure ≥3 times if initially below threshold)
- Assess comorbidities, inhaler technique, adherence
Add-on options:
| Biologic | Target | Indication |
|---|---|---|
| Anti-IgE (omalizumab) | IgE | Allergic asthma |
| Anti-IL5/5R (mepolizumab, benralizumab) | Eosinophilic inflammation | Eosinophilic asthma |
| Anti-IL4Rα (dupilumab) | IL-4/IL-13 | T2 asthma |
| Anti-TSLP (tezepelumab) | TSLP | Broad T2 asthma |
| LAMA (tiotropium) | Muscarinic | Add-on at all severe steps |
Children 6–11 Years
A single track approach (no ICS-formoterol MART):
| Step | Controller | Reliever |
|---|---|---|
| Step 1 | None | SABA (+ low-dose ICS simultaneously) |
| Step 2 | Low-dose ICS daily | SABA |
| Step 3 | Low-dose ICS-LABA or medium-dose ICS | SABA |
| Step 4 | Medium-dose ICS-LABA | SABA |
| Step 5 | High-dose ICS-LABA; refer for biologic assessment | SABA |
Second-line controller at any step: LTRA (montelukast)
Children ≤5 Years
- Diagnosis is clinical (no spirometry possible)
- Step 1–2: As-needed SABA ± low-dose ICS trial
- Step 3: Daily low-dose ICS; LTRA as alternative
- Step 4: Refer to specialist; medium-dose ICS or add LTRA
- Biologics generally not recommended in this age group
Key GINA 2025 Updates (vs. Prior Years)
| Change | Detail |
|---|---|
| Track 2, Step 4 | Changed from medium-to-high dose ICS-LABA → medium-dose ICS-LABA only (minimise high-dose ICS adverse effects) |
| T2 biomarkers | Updated guidance on BEC/FeNO interpretation; measure ≥3× before deciding on biologics |
| Severe asthma decision tree | Diagnosis confirmation moved to Stage 5 of specialist workup |
| Young children exacerbations | Nebulised albuterol dose clarified: 2.5 mg (not 0.25 mg) for ≤5 years |
| Non-pharmacologic strategies | Smoking cessation, physical activity, weight reduction, vaccinations, HDM SLIT allergen immunotherapy |
ICS Dose Categories (BDP-equivalent, adults ≥12 yrs)
| Category | Dose (mcg/day) |
|---|---|
| Low | ≤250 |
| Medium | 251–500 |
| High | >500 |
2021 Asthma Management Continuum Diagram
The continuum above (from the textbook library) illustrates the escalating stepwise approach — from foundational environmental control and diagnosis confirmation, through ICS escalation, up to add-on LABA/LTRA/tiotropium and biologic therapy for severe disease.
Sources: GINA 2025 Summary Guide | GINA 2025 Update Overview | Medical Textbook Library (Harriet Lane Handbook, 23rd ed.)
This is a shared conversation. Sign in to Orris to start your own chat.